1. A novel anti-androgen candidate galeterone acts by targeting USP12, a deubiquitinating enzyme that controls prostate cancer growth and survival. (December 2016) Authors: McClurg, U.; Dransfield, D.; Namdev, N.; Jacoby, D.; Chit, N.; Nakjang, S.; Edwards, J.; McCracken, S.; Robson, C. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Targeting cell metabolism to improve prostate cancer therapeutics. (July 2016) Authors: Bedaj, M.; Rao, K.; Robson, C.; McCracken, S. Journal: European journal of cancer Issue: Volume 61(2016)Supplement 1 Page Start: S144 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The role of the HER2 and HER3 in prostate cancer and their potential as therapeutic targets. (July 2016) Authors: Rao, K.; Gaughan, L.; Robson, C.; McCracken, S. Journal: European journal of cancer Issue: Volume 61(2016)Supplement 1 Page Start: S177 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗